Evra Evrópusambandið - íslenska - EMA (European Medicines Agency)

evra

gedeon richter plc. - norelgestromin, ethinyl estradiol - getnaðarvörn - hormón kynlíf og stillum kynfæri - konur getnaðarvörn. evra er ætlað konum frjósöm aldri. Öryggi og verkun hefur verið stofnað í konur á aldrinum 18 til 45 ára.

Waylivra Evrópusambandið - íslenska - EMA (European Medicines Agency)

waylivra

akcea therapeutics ireland limited - volanesorsen járn - hyperlipoproteinemia type i - Önnur fitu breyta lyfjum - waylivra er ætlað sem viðbót til að mataræði í fullorðinn sjúklinga með erfðafræðilega staðfest ættingja chylomicronemia heilkenni (gegn) og í mikilli hættu fyrir lyf og sem svar við mataræði og þríglýseríða lækka meðferð hefur verið ófullnægjandi.

Comirnaty Evrópusambandið - íslenska - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - bóluefni - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Aripiprazole Sandoz Evrópusambandið - íslenska - EMA (European Medicines Agency)

aripiprazole sandoz

sandoz gmbh - aripíprazól - schizophrenia; bipolar disorder - psycholeptics - aripiprazol sandoz er ætlað til meðferðar á geðklofa hjá fullorðnum og unglingum 15 ára og eldri. sjúklingum sandoz er ætlað fyrir meðferð í meðallagi til alvarlega oflæti þáttur í geðhvarfasýki ég ringulreið og til að fyrirbyggja nýja oflæti þáttur í fullorðnir sem upplifað aðallega oflæti þætti og sem oflæti þáttur brugðist við sjúklingum meðferð. sjúklingum sandoz er ætlað fyrir meðferð upp til 12 vikur í meðallagi að alvarlega oflæti þáttur í geðhvarfasýki ég röskun á unglingar eru 13 ára og eldri.

Nuvaxovid Evrópusambandið - íslenska - EMA (European Medicines Agency)

nuvaxovid

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Xevudy Evrópusambandið - íslenska - EMA (European Medicines Agency)

xevudy

glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - Ónæmiskerfið sera og mótefni, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.

Evusheld Evrópusambandið - íslenska - EMA (European Medicines Agency)

evusheld

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

Dutrebis Evrópusambandið - íslenska - EMA (European Medicines Agency)

dutrebis

merck sharp dohme limited - áhrif, raltegravir kalíum - hiv sýkingar - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - dutrebis er ætlað ásamt öðrum anti‑retróveira lyf til meðferð hiv veira (hiv‑1) sýkingu í fullorðnir, unglingar, og börn frá 6 ára og vega að minnsta kosti 30 kg án staðar eða fortíð vísbendingar um friðhelgi andstöðu við veirum á höfða (integrase Þræði flytja hemil) og nrti (núkleósíð vixlrita hemil) flokkum (sjá kafla 4. 2, 4. 4 og 5.

Bimervax Evrópusambandið - íslenska - EMA (European Medicines Agency)

bimervax

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - bóluefni - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.